Nexelis to Acquire ImmunXperts

Q² Solutions (IQVIA) Acquires Nexelis from Ampersand Capital Partners

January 10, 2022

Healthcare Services

Ampersand Capital Partners sold its portfolio company Nexelis to Q² Solutions, a wholly owned subsidiary of IQVIA, Inc. Nexelis, a Laval, Quebec–based provider of assay development and advanced clinical-trial laboratory testing with five operating sites in North America and Europe, will be integrated into IQVIA's global laboratory services to expand capabilities and capacity for vaccine, immunology and other drug-development testing.

Nexelis Acquires AIT Bioscience

July 22, 2020

Healthcare Services

Nexelis, a portfolio company of Ampersand Capital Partners, has acquired AIT Bioscience, an Indianapolis-based integrated bioanalytical CRO with LC‑MS and immunoassay testing capabilities. The add-on expands Nexelis' bioanalytical services (including large-molecule mass spectrometry) and establishes operations in Indianapolis to support future growth and faster turnaround times.

Nexelis Acquires GSK Vaccines Clinical Bioanalytical Laboratory (Marburg)

January 20, 2021

Biotechnology

Nexelis, a portfolio company of Ampersand Capital Partners, has signed an asset purchase agreement to acquire GSK's GCLP-certified clinical bioanalytical laboratory in Marburg, Germany. Approximately 80 scientists and analysts will transfer to Nexelis, which also entered a five-year strategic collaboration with GSK to continue supporting vaccine development while expanding Nexelis' assay development and high-throughput clinical testing capabilities in Europe.

Astellas Pharma Acquires Xyphos Biosciences

December 26, 2019

Biotechnology

Astellas Pharma has acquired Xyphos Biosciences, gaining Xyphos' ACCEL convertible-CAR technology platform and immuno-oncology talent. The deal included $120 million paid at closing and potential milestone payments bringing the total transaction value to up to $665 million.

PerkinElmer Acquires Nexcelom Bioscience for $260M

May 13, 2021

Medical Devices

PerkinElmer, Inc. agreed to acquire Nexcelom Bioscience for $260 million in cash, a deal announced in 2021 and completed in June 2021. Nexcelom, a Lawrence, Massachusetts–based maker of automated cell counters, image cytometry systems, consumables and reagents (~130 employees, projected 2021 revenue ~$40M), was owned by its founders and Ampersand Capital Partners.

AVS Bio Acquires ImmunoPrecise Antibodies (Europe) B.V.

August 6, 2025

Biotechnology

AVS Bio, a portfolio company of Arlington Capital Partners, has acquired ImmunoPrecise Antibodies (Europe) B.V., a carve-out from ImmunoPrecise Antibodies Ltd. The acquisition expands AVS Bio's European footprint and adds antibody discovery, recombinant protein expression, and organoid growth factor development capabilities to its biologics services platform.